2696 Stock Overview
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Shanghai Henlius Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$16.34 |
| 52 Week High | HK$16.48 |
| 52 Week Low | HK$9.60 |
| Beta | 0.88 |
| 1 Month Change | 17.05% |
| 3 Month Change | 15.89% |
| 1 Year Change | 13.47% |
| 3 Year Change | -63.12% |
| 5 Year Change | n/a |
| Change since IPO | -66.96% |
Recent News & Updates
Recent updates
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 25
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking
Mar 10Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load
Dec 31The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business
Nov 25Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
Sep 18Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet
Aug 03Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?
May 31Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues
Apr 06Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
Sep 22Shareholder Returns
| 2696 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 11.5% | 5.7% | 3.6% |
| 1Y | 13.5% | -40.7% | -10.1% |
Return vs Industry: 2696 exceeded the Hong Kong Biotechs industry which returned -40.7% over the past year.
Return vs Market: 2696 exceeded the Hong Kong Market which returned -10.1% over the past year.
Price Volatility
| 2696 volatility | |
|---|---|
| 2696 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2696 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2696's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 3,637 | Jason Zhu | www.henlius.com |
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer; and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous-cell carcinomas, gastric cancer, small cell lung cancer, hepatocellular carcinoma, metastatic colorectal cancer, solid tumors, SCCHN, sqNSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, and HLX51 to treat solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; and HLX14 to treat osteoporosis.
Shanghai Henlius Biotech, Inc. Fundamentals Summary
| 2696 fundamental statistics | |
|---|---|
| Market cap | HK$8.88b |
| Earnings (TTM) | HK$589.96m |
| Revenue (TTM) | HK$5.83b |
15.1x
P/E Ratio1.5x
P/S RatioIs 2696 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2696 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.39b |
| Cost of Revenue | CN¥1.48b |
| Gross Profit | CN¥3.92b |
| Other Expenses | CN¥3.37b |
| Earnings | CN¥546.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 72.64% |
| Net Profit Margin | 10.12% |
| Debt/Equity Ratio | 174.2% |
How did 2696 perform over the long term?
See historical performance and comparison